JPWO2020264509A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020264509A5
JPWO2020264509A5 JP2021577424A JP2021577424A JPWO2020264509A5 JP WO2020264509 A5 JPWO2020264509 A5 JP WO2020264509A5 JP 2021577424 A JP2021577424 A JP 2021577424A JP 2021577424 A JP2021577424 A JP 2021577424A JP WO2020264509 A5 JPWO2020264509 A5 JP WO2020264509A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
alkyl
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021577424A
Other languages
English (en)
Japanese (ja)
Other versions
JP7787635B2 (ja
JP2022538299A (ja
JP2022538299A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/040153 external-priority patent/WO2020264509A1/en
Publication of JP2022538299A publication Critical patent/JP2022538299A/ja
Publication of JPWO2020264509A5 publication Critical patent/JPWO2020264509A5/ja
Publication of JP2022538299A5 publication Critical patent/JP2022538299A5/ja
Priority to JP2025000024A priority Critical patent/JP2025060984A/ja
Application granted granted Critical
Publication of JP7787635B2 publication Critical patent/JP7787635B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021577424A 2019-06-27 2020-06-29 Cns障害を治療するための組成物及び方法 Active JP7787635B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025000024A JP2025060984A (ja) 2019-06-27 2025-01-05 Cns障害を治療するための組成物及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962867618P 2019-06-27 2019-06-27
US62/867,618 2019-06-27
PCT/US2020/040153 WO2020264509A1 (en) 2019-06-27 2020-06-29 Compositions and methods for treating cns disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025000024A Division JP2025060984A (ja) 2019-06-27 2025-01-05 Cns障害を治療するための組成物及び方法

Publications (4)

Publication Number Publication Date
JP2022538299A JP2022538299A (ja) 2022-09-01
JPWO2020264509A5 true JPWO2020264509A5 (https=) 2023-07-07
JP2022538299A5 JP2022538299A5 (https=) 2023-07-07
JP7787635B2 JP7787635B2 (ja) 2025-12-17

Family

ID=71728947

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021577424A Active JP7787635B2 (ja) 2019-06-27 2020-06-29 Cns障害を治療するための組成物及び方法
JP2025000024A Pending JP2025060984A (ja) 2019-06-27 2025-01-05 Cns障害を治療するための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025000024A Pending JP2025060984A (ja) 2019-06-27 2025-01-05 Cns障害を治療するための組成物及び方法

Country Status (13)

Country Link
US (1) US12552829B2 (https=)
EP (1) EP3990469A1 (https=)
JP (2) JP7787635B2 (https=)
KR (1) KR20220038680A (https=)
CN (1) CN114391019A (https=)
AR (1) AR119305A1 (https=)
AU (1) AU2020302748A1 (https=)
BR (1) BR112021026462A2 (https=)
CA (1) CA3143509A1 (https=)
IL (1) IL289172A (https=)
MX (3) MX2021015942A (https=)
TW (1) TWI896547B (https=)
WO (1) WO2020264509A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015002252A (es) 2012-08-21 2015-07-21 Sage Therapeutics Inc Metodos para tratar epilepsia o estado de epilepsia.
JP6470258B2 (ja) 2013-04-17 2019-02-13 セージ セラピューティクス, インコーポレイテッド 19−ノルc3,3−ジ置換c21−n−ピラゾリルステロイドおよびその使用方法
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
TWI904593B (zh) 2016-08-23 2025-11-11 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
EP3720867A1 (en) 2017-12-08 2020-10-14 Sage Therapeutics, Inc. Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
CR20240234A (es) 2019-05-31 2024-07-09 Sage Therapeutics Inc ESTEROIDES NEUROACTIVOS Y COMPOSICIONES DE ESTOS (Divisional 2021-629)
JP7787635B2 (ja) * 2019-06-27 2025-12-17 セージ セラピューティクス, エルエルシー Cns障害を治療するための組成物及び方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2969M (fr) 1963-05-22 1964-11-30 Roussel Uclaf Nouveau médicament notamment pour le traitement des spasmes d'origine coronarienne on viscérale.
ES432106A1 (es) 1973-11-30 1976-11-01 Schering Ag Procedimiento para la preparacion de d-homo-20-cetopregna- nos.
IL48628A0 (en) 1974-12-23 1976-02-29 Schering Ag D-homo-20-keto-pregnanes and process for their manufactur
GB1570394A (en) 1976-01-06 1980-07-02 Glaxo Lab Ltd 11-acyloxy-3-hydroxy steroids
US4060295A (en) 1976-03-15 1977-11-29 Molex Incorporated Zero insertion force printed circuit board edge connector assembly
GB1581234A (en) 1976-04-05 1980-12-10 Glaxo Operations Ltd 11a - amino - 3a - hydroxysteroids
GB1581235A (en) 1977-04-04 1980-12-10 Glaxo Operations Ltd 11a-amino-3a-hydroxy-steroids
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
FI972202L (fi) 1994-11-23 1997-07-17 Cocensys Inc Androstaanit ja pregnaanit GABA-reseptoreiden allosteeriseen muunteluun
AU3967297A (en) 1996-08-01 1998-02-25 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
WO2005105822A2 (en) * 2004-04-23 2005-11-10 Euro-Celtique S.A. 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
HRP20230747T1 (hr) 2011-09-08 2024-01-05 Sage Therapeutics, Inc. Neuroaktivni steroidi, pripravci i njihova uporaba
JP6470258B2 (ja) 2013-04-17 2019-02-13 セージ セラピューティクス, インコーポレイテッド 19−ノルc3,3−ジ置換c21−n−ピラゾリルステロイドおよびその使用方法
HRP20201126T1 (hr) 2014-05-29 2020-12-11 Sage Therapeutics, Inc. Neuroaktivni steroidi, njihovi pripravci i uporabe
US10577390B2 (en) 2014-10-16 2020-03-03 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
WO2017049044A1 (en) 2015-09-16 2017-03-23 Bartolucci Giampiero Ursodeoxycholic acid and brain disorders
HK1258616A1 (zh) 2016-03-08 2019-11-15 Sage Therapeutics, Inc. 神经活性类固醇、组合物、及其用途
US20190233465A1 (en) * 2016-07-11 2019-08-01 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
EP3641779B1 (en) * 2017-06-23 2024-02-28 The Board of Trustees of the University of Illinois Treatment of neuropsychiatric disorders with neurosteroids and analogues thereof
WO2019041078A1 (en) 2017-08-28 2019-03-07 Zhejiang Jiachi Pharmaceutical Development Ltd. ASYMMETRIC SYNTHESIS AND USES OF COMPOUNDS IN TREATMENT OF DISEASES
EP3678670A1 (en) * 2017-09-07 2020-07-15 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
CN111741965B (zh) 2017-12-22 2024-06-25 萨奇治疗股份有限公司 治疗中枢神经系统疾病的组合物和方法
CN114656514B (zh) 2018-02-11 2024-05-14 江苏豪森药业集团有限公司 一种甾族类衍生物调节剂及其制备方法和应用
IL283629B2 (en) * 2018-12-05 2026-03-01 Sage Therapeutics Inc Neuroactive steroids and methods of using them
CN116589521B (zh) 2019-01-08 2025-07-11 成都康弘药业集团股份有限公司 甾体类化合物、用途及其制备方法
WO2020210117A1 (en) 2019-04-08 2020-10-15 Athenen Therapeutics, Inc. Steroids with altered pharmacokinetic properties and methods of use thereof
WO2020210116A1 (en) 2019-04-08 2020-10-15 Athenen Therapeutics, Inc. Steroids with altered pharmacokinetic properties and methods of use thereof
CR20240234A (es) 2019-05-31 2024-07-09 Sage Therapeutics Inc ESTEROIDES NEUROACTIVOS Y COMPOSICIONES DE ESTOS (Divisional 2021-629)
US20230257415A1 (en) 2019-06-27 2023-08-17 Sage Therapeutics, Inc. Compounds for treating cns disorders
JP7787635B2 (ja) 2019-06-27 2025-12-17 セージ セラピューティクス, エルエルシー Cns障害を治療するための組成物及び方法
AU2020304673A1 (en) 2019-06-27 2022-01-20 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
WO2022115381A1 (en) * 2020-11-25 2022-06-02 Sage Therapeutics, Onc. Compositions and methods for treating cns disorders cross reference to related application

Similar Documents

Publication Publication Date Title
RU2405774C2 (ru) Гетероциклические ингибиторы аспартилпротеазы
RU2011152891A (ru) Диарилгидантоины
JP2019512485A5 (https=)
JP2008508192A5 (https=)
JP2011520815A5 (https=)
JPWO2020264509A5 (https=)
JPWO2020123827A5 (https=)
JP2007535551A5 (https=)
JPWO2020264512A5 (https=)
JP2020527175A5 (https=)
JPWO2022000091A5 (https=)
JP2022137237A5 (https=)
JPWO2023042879A5 (https=)
RU2016111138A (ru) Гетероциклические соединения и способы их применения
JPWO2020118060A5 (https=)
JPWO2020139988A5 (https=)
JP2023164918A5 (https=)
JPWO2021030555A5 (https=)
CA2547347A1 (en) Diazaindole-dicarbonyl-piperazinyl antiviral agents
RU2007116987A (ru) Новые соединения
JP2021534254A5 (ja) 心臓弁疾患を治療するための医薬組成物
JPWO2020132504A5 (https=)
JP2021529778A5 (https=)
AR048393A1 (es) Piperazinas utiles para el tratamiento del dolor
JP2021514399A5 (https=)